title: Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.
abstract: To test whether the protective effects of attenuated simian immunodeficiency virus vaccines in macaques were applicable to the human immunodeficiency virus type 1 (HIV-1)-chimpanzee system, two groups of animals, previously infected with HIV-1(IIIB) or HIV-1(SF2) were each challenged with a heterologous clade B virus, HIV-1(DH12). Following challenge, the parameters measured included virus isolation (from plasma, peripheral blood mononuclear cells, and lymph node tissue); quantitative DNA PCR using primers capable of distinguishing HIV-1(IIIB), HIV-1(SF2), and HIV-1(DH12) from one another; and serologic assays to monitor changes in binding and neutralizing antibodies. In contrast to an HIV-1-naive chimpanzee that rapidly became infected following the inoculation of HIV-1(DH12), the two chimpanzees previously infected with HIV-1(IIIB) resisted repeated and escalating inoculations of HIV-1(DH12), as monitored by virus isolation and PCR. The two animals previously infected with HIV-1(SF2) became infected with HIV-1(DH12) but in contrast to the case with the HIV-1-naive chimpanzee, no cell-free viral RNA was detected in the plasma by the branched DNA procedure and levels of peripheral blood mononuclear cell-associated viral DNA were reduced 35- to 50-fold.
authors.affiliation: Laboratory of Molecular Microbiology, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shibata
authors.forename: C
authors.initials: C
authors.lastname: Siemon
authors.forename: M W
authors.initials: MW
authors.lastname: Cho
authors.forename: L O
authors.initials: LO
authors.lastname: Arthur
authors.forename: S M
authors.initials: SM
authors.lastname: Nigida
authors.forename: T
authors.initials: T
authors.lastname: Matthews
authors.forename: L A
authors.initials: LA
authors.lastname: Sawyer
authors.forename: A
authors.initials: A
authors.lastname: Schultz
authors.forename: K K
authors.initials: KK
authors.lastname: Murthy
authors.forename: Z
authors.initials: Z
authors.lastname: Israel
authors.forename: A
authors.initials: A
authors.lastname: Javadian
authors.forename: P
authors.initials: P
authors.lastname: Frost
authors.forename: R C
authors.initials: RC
authors.lastname: Kennedy
authors.forename: H C
authors.initials: HC
authors.lastname: Lane
authors.forename: M A
authors.initials: MA
authors.lastname: Martin
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D001483:Base Sequence; D004279:DNA, Viral / Q000097:blood; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007113:Immunity, Innate; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D002679:Pan troglodytes; D012367:RNA, Viral / Q000097:blood; D014407:Tumor Cells, Cultured; D014613:Vaccines, Attenuated / Q000276:immunology; D014762:Viral Interference
chemical_list: D016915:AIDS Vaccines; D004279:DNA, Viral; D015483:HIV Antibodies; D012367:RNA, Viral; D014613:Vaccines, Attenuated